Concepts (321)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 4 | 2020 | 91 | 2.240 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2019 | 15 | 1.740 |
Why?
|
| Neoplasms | 12 | 2024 | 762 | 1.690 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2019 | 11 | 1.550 |
Why?
|
| Patient Education as Topic | 2 | 2020 | 265 | 1.100 |
Why?
|
| Models, Statistical | 4 | 2018 | 180 | 0.980 |
Why?
|
| Prediabetic State | 2 | 2023 | 74 | 0.900 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2015 | 42 | 0.880 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 100 | 0.850 |
Why?
|
| Humans | 62 | 2024 | 32968 | 0.840 |
Why?
|
| Orthopedic Nursing | 2 | 2020 | 4 | 0.810 |
Why?
|
| Preoperative Care | 2 | 2020 | 123 | 0.760 |
Why?
|
| Perception | 2 | 2020 | 104 | 0.740 |
Why?
|
| Treatment Outcome | 9 | 2024 | 3460 | 0.710 |
Why?
|
| Cardiovascular Diseases | 3 | 2024 | 1152 | 0.680 |
Why?
|
| Research Design | 5 | 2023 | 334 | 0.670 |
Why?
|
| Patient Discharge | 2 | 2019 | 205 | 0.660 |
Why?
|
| Nurses | 1 | 2020 | 15 | 0.630 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 1477 | 0.610 |
Why?
|
| Multiple Myeloma | 1 | 2019 | 20 | 0.600 |
Why?
|
| Tretinoin | 1 | 2019 | 33 | 0.600 |
Why?
|
| Statistics as Topic | 1 | 2018 | 104 | 0.540 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 241 | 0.530 |
Why?
|
| Healthcare Disparities | 2 | 2017 | 178 | 0.520 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 429 | 0.520 |
Why?
|
| Medulloblastoma | 1 | 2017 | 7 | 0.520 |
Why?
|
| Cerebellar Neoplasms | 1 | 2017 | 11 | 0.520 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 541 | 0.520 |
Why?
|
| Adult | 23 | 2024 | 9586 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 599 | 0.510 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 60 | 0.500 |
Why?
|
| Female | 33 | 2024 | 20375 | 0.500 |
Why?
|
| Vaginal Smears | 2 | 2014 | 9 | 0.490 |
Why?
|
| Medical Records | 2 | 2013 | 77 | 0.480 |
Why?
|
| Social Work | 2 | 2024 | 8 | 0.470 |
Why?
|
| Middle Aged | 24 | 2024 | 12203 | 0.430 |
Why?
|
| Male | 29 | 2024 | 19754 | 0.420 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2018 | 95 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 3 | 2024 | 134 | 0.400 |
Why?
|
| Young Adult | 10 | 2018 | 2738 | 0.390 |
Why?
|
| Mass Screening | 2 | 2022 | 268 | 0.380 |
Why?
|
| Kentucky | 5 | 2015 | 17 | 0.380 |
Why?
|
| Aging | 4 | 2018 | 955 | 0.380 |
Why?
|
| Computer Simulation | 4 | 2018 | 224 | 0.360 |
Why?
|
| Lip | 3 | 2017 | 7 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 175 | 0.360 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 222 | 0.350 |
Why?
|
| Patient Compliance | 1 | 2012 | 219 | 0.340 |
Why?
|
| Telemedicine | 2 | 2023 | 118 | 0.340 |
Why?
|
| Postural Balance | 2 | 2018 | 180 | 0.330 |
Why?
|
| Quality of Life | 6 | 2024 | 976 | 0.320 |
Why?
|
| Food Supply | 2 | 2011 | 67 | 0.320 |
Why?
|
| Aged | 17 | 2024 | 10637 | 0.320 |
Why?
|
| Smoking Cessation | 2 | 2023 | 216 | 0.310 |
Why?
|
| Adolescent | 9 | 2018 | 3643 | 0.300 |
Why?
|
| Breast Neoplasms | 3 | 2024 | 754 | 0.280 |
Why?
|
| Lymphocyte Depletion | 1 | 2018 | 17 | 0.280 |
Why?
|
| Voice Quality | 2 | 2018 | 6 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 2 | 2022 | 543 | 0.270 |
Why?
|
| Laryngeal Neoplasms | 2 | 2017 | 16 | 0.260 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 129 | 0.260 |
Why?
|
| Guideline Adherence | 2 | 2014 | 120 | 0.250 |
Why?
|
| United States | 8 | 2024 | 4132 | 0.250 |
Why?
|
| Socioeconomic Factors | 4 | 2015 | 436 | 0.250 |
Why?
|
| Vibration | 2 | 2015 | 10 | 0.240 |
Why?
|
| Doxorubicin | 2 | 2017 | 84 | 0.240 |
Why?
|
| Appalachian Region | 3 | 2015 | 20 | 0.240 |
Why?
|
| Obesity | 2 | 2023 | 1179 | 0.230 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 158 | 0.220 |
Why?
|
| Touch Perception | 1 | 2014 | 2 | 0.210 |
Why?
|
| Communications Media | 1 | 2024 | 4 | 0.210 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 19 | 0.210 |
Why?
|
| Xerostomia | 1 | 2024 | 30 | 0.210 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 9 | 0.210 |
Why?
|
| Papillomavirus Infections | 2 | 2015 | 68 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 622 | 0.210 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 2287 | 0.210 |
Why?
|
| Nurse Practitioners | 1 | 2024 | 11 | 0.210 |
Why?
|
| Postoperative Complications | 2 | 2021 | 828 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2017 | 147 | 0.210 |
Why?
|
| Sirolimus | 1 | 2013 | 33 | 0.200 |
Why?
|
| Needs Assessment | 1 | 2024 | 75 | 0.200 |
Why?
|
| Pesticides | 1 | 2016 | 196 | 0.200 |
Why?
|
| Gamma Rays | 1 | 2013 | 25 | 0.200 |
Why?
|
| Tumor Burden | 1 | 2013 | 61 | 0.200 |
Why?
|
| Treatment Failure | 1 | 2013 | 156 | 0.200 |
Why?
|
| Radiation Injuries | 1 | 2024 | 78 | 0.200 |
Why?
|
| Pilot Projects | 5 | 2023 | 566 | 0.200 |
Why?
|
| Risk Factors | 4 | 2024 | 4001 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2013 | 84 | 0.200 |
Why?
|
| Occupational Exposure | 1 | 2016 | 231 | 0.200 |
Why?
|
| Estradiol | 1 | 2013 | 121 | 0.200 |
Why?
|
| Tobacco Use Cessation | 1 | 2023 | 22 | 0.190 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 240 | 0.190 |
Why?
|
| Endometrial Neoplasms | 1 | 2023 | 48 | 0.190 |
Why?
|
| Medical Oncology | 4 | 2024 | 92 | 0.190 |
Why?
|
| Transients and Migrants | 1 | 2016 | 298 | 0.190 |
Why?
|
| Social Support | 2 | 2024 | 183 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1581 | 0.190 |
Why?
|
| Caregivers | 1 | 2024 | 121 | 0.190 |
Why?
|
| Nutritional Status | 1 | 2013 | 78 | 0.190 |
Why?
|
| Age Factors | 4 | 2018 | 1202 | 0.190 |
Why?
|
| Music Therapy | 1 | 2022 | 5 | 0.180 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 91 | 0.180 |
Why?
|
| Vitamin D | 1 | 2013 | 189 | 0.170 |
Why?
|
| Overweight | 1 | 2023 | 263 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 1 | 2021 | 14 | 0.170 |
Why?
|
| Muscle Weakness | 1 | 2021 | 36 | 0.170 |
Why?
|
| Quadriceps Muscle | 1 | 2021 | 33 | 0.170 |
Why?
|
| Knee Injuries | 1 | 2021 | 40 | 0.170 |
Why?
|
| Geography | 1 | 2010 | 35 | 0.160 |
Why?
|
| Child | 4 | 2023 | 2478 | 0.160 |
Why?
|
| Evidence-Based Practice | 1 | 2020 | 28 | 0.160 |
Why?
|
| Infant | 3 | 2018 | 1083 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2013 | 362 | 0.160 |
Why?
|
| Hispanic Americans | 1 | 2016 | 930 | 0.160 |
Why?
|
| Child, Preschool | 3 | 2018 | 1282 | 0.160 |
Why?
|
| Interviews as Topic | 1 | 2020 | 273 | 0.150 |
Why?
|
| Qualitative Research | 1 | 2020 | 201 | 0.150 |
Why?
|
| Prostatic Neoplasms | 1 | 2024 | 476 | 0.150 |
Why?
|
| Behavior Therapy | 1 | 2019 | 103 | 0.150 |
Why?
|
| Algorithms | 2 | 2018 | 517 | 0.150 |
Why?
|
| Vaccination | 1 | 2010 | 146 | 0.150 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 125 | 0.150 |
Why?
|
| Brain | 2 | 2017 | 949 | 0.150 |
Why?
|
| Sample Size | 1 | 2018 | 39 | 0.150 |
Why?
|
| Muscle Fatigue | 1 | 2018 | 13 | 0.140 |
Why?
|
| Voice Disorders | 1 | 2018 | 5 | 0.140 |
Why?
|
| Cohort Studies | 5 | 2017 | 1852 | 0.140 |
Why?
|
| Infant, Newborn | 2 | 2018 | 694 | 0.140 |
Why?
|
| Survivors | 3 | 2024 | 168 | 0.140 |
Why?
|
| Shoulder | 1 | 2018 | 50 | 0.140 |
Why?
|
| Sports Medicine | 1 | 2018 | 27 | 0.140 |
Why?
|
| Rural Population | 2 | 2015 | 286 | 0.140 |
Why?
|
| Probability | 1 | 2018 | 157 | 0.140 |
Why?
|
| Voice Training | 1 | 2017 | 1 | 0.140 |
Why?
|
| Cluster Analysis | 2 | 2012 | 126 | 0.140 |
Why?
|
| Range of Motion, Articular | 1 | 2019 | 195 | 0.140 |
Why?
|
| Brain Concussion | 1 | 2018 | 65 | 0.140 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 647 | 0.140 |
Why?
|
| Muscle Contraction | 1 | 2018 | 113 | 0.130 |
Why?
|
| Laryngectomy | 1 | 2017 | 3 | 0.130 |
Why?
|
| Patient Readmission | 1 | 2019 | 135 | 0.130 |
Why?
|
| Adipose Tissue, Brown | 1 | 2017 | 8 | 0.130 |
Why?
|
| Propranolol | 1 | 2017 | 17 | 0.130 |
Why?
|
| Length of Stay | 1 | 2019 | 329 | 0.130 |
Why?
|
| Vocal Cords | 1 | 2017 | 9 | 0.130 |
Why?
|
| Visual Perception | 1 | 2018 | 116 | 0.130 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2017 | 51 | 0.130 |
Why?
|
| Myocytes, Cardiac | 1 | 2017 | 95 | 0.130 |
Why?
|
| Otolaryngology | 1 | 2017 | 17 | 0.130 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 363 | 0.130 |
Why?
|
| Athletic Injuries | 1 | 2018 | 95 | 0.130 |
Why?
|
| Face | 1 | 2017 | 29 | 0.130 |
Why?
|
| Tracheostomy | 1 | 2017 | 28 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 166 | 0.130 |
Why?
|
| Demography | 1 | 2017 | 110 | 0.130 |
Why?
|
| Intraoperative Complications | 1 | 2017 | 59 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2018 | 3708 | 0.130 |
Why?
|
| Sensation | 1 | 2017 | 57 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2017 | 134 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 34 | 0.120 |
Why?
|
| Stroke | 1 | 2022 | 610 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2017 | 116 | 0.120 |
Why?
|
| Glioblastoma | 1 | 2018 | 157 | 0.120 |
Why?
|
| Positron-Emission Tomography | 1 | 2017 | 168 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 113 | 0.120 |
Why?
|
| Muscle, Skeletal | 2 | 2017 | 537 | 0.120 |
Why?
|
| Auditory Threshold | 1 | 2015 | 3 | 0.120 |
Why?
|
| Mesna | 1 | 2015 | 3 | 0.110 |
Why?
|
| Genes, p16 | 1 | 2015 | 1 | 0.110 |
Why?
|
| Protective Agents | 1 | 2015 | 4 | 0.110 |
Why?
|
| SEER Program | 1 | 2015 | 33 | 0.110 |
Why?
|
| Survival Rate | 3 | 2018 | 895 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2015 | 46 | 0.110 |
Why?
|
| Carboplatin | 1 | 2015 | 51 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 765 | 0.110 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 22 | 0.110 |
Why?
|
| Paclitaxel | 1 | 2015 | 67 | 0.110 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2015 | 22 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 50 | 0.110 |
Why?
|
| Lymphocytes | 1 | 2015 | 59 | 0.110 |
Why?
|
| Meningioma | 1 | 2015 | 58 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2015 | 44 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 332 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 213 | 0.100 |
Why?
|
| Sigmoidoscopy | 1 | 2013 | 3 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2024 | 19 | 0.100 |
Why?
|
| Directive Counseling | 1 | 2013 | 17 | 0.100 |
Why?
|
| Colonoscopy | 1 | 2013 | 45 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 4065 | 0.100 |
Why?
|
| Program Evaluation | 1 | 2013 | 181 | 0.100 |
Why?
|
| Hospitals, Public | 1 | 2012 | 5 | 0.100 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 120 | 0.100 |
Why?
|
| Time Factors | 1 | 2018 | 2195 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2014 | 134 | 0.090 |
Why?
|
| Rural Health Services | 1 | 2012 | 31 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2012 | 73 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 360 | 0.090 |
Why?
|
| Lung | 2 | 2023 | 268 | 0.080 |
Why?
|
| Restaurants | 2 | 2011 | 10 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2024 | 82 | 0.080 |
Why?
|
| Single-Blind Method | 2 | 2022 | 196 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 880 | 0.080 |
Why?
|
| Hypertension | 1 | 2017 | 983 | 0.080 |
Why?
|
| Renal Dialysis | 2 | 2022 | 280 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 883 | 0.080 |
Why?
|
| Depression | 2 | 2023 | 448 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 457 | 0.070 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 326 | 0.070 |
Why?
|
| Blood Pressure | 2 | 2024 | 867 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 573 | 0.060 |
Why?
|
| Population Surveillance | 2 | 2018 | 128 | 0.060 |
Why?
|
| Oxidation-Reduction | 2 | 2017 | 269 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2018 | 486 | 0.060 |
Why?
|
| Cancer Care Facilities | 1 | 2024 | 11 | 0.050 |
Why?
|
| Sensory Thresholds | 1 | 2014 | 28 | 0.050 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 894 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2013 | 43 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 80 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 106 | 0.050 |
Why?
|
| Micronutrients | 1 | 2013 | 20 | 0.050 |
Why?
|
| Dyspnea | 1 | 2023 | 35 | 0.050 |
Why?
|
| Communication | 1 | 2024 | 141 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2024 | 147 | 0.050 |
Why?
|
| Glucose | 1 | 2024 | 188 | 0.050 |
Why?
|
| Cholesterol | 1 | 2024 | 255 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 212 | 0.050 |
Why?
|
| Medicare | 1 | 2024 | 213 | 0.050 |
Why?
|
| Patient Participation | 1 | 2023 | 87 | 0.050 |
Why?
|
| Urban Population | 1 | 2013 | 93 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 241 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2024 | 308 | 0.050 |
Why?
|
| Urea | 1 | 2021 | 37 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2023 | 308 | 0.040 |
Why?
|
| Affect | 1 | 2022 | 70 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 2338 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2013 | 467 | 0.040 |
Why?
|
| Health Status | 1 | 2024 | 403 | 0.040 |
Why?
|
| North Carolina | 1 | 2016 | 1550 | 0.040 |
Why?
|
| Anxiety | 1 | 2023 | 195 | 0.040 |
Why?
|
| Food Industry | 1 | 2011 | 9 | 0.040 |
Why?
|
| Monte Carlo Method | 1 | 2011 | 19 | 0.040 |
Why?
|
| South Carolina | 1 | 2011 | 32 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2012 | 138 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 384 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2023 | 282 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 310 | 0.040 |
Why?
|
| Logistic Models | 1 | 2013 | 783 | 0.040 |
Why?
|
| Population Density | 1 | 2010 | 9 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2010 | 43 | 0.040 |
Why?
|
| Prevalence | 1 | 2013 | 1002 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2021 | 159 | 0.040 |
Why?
|
| Data Collection | 1 | 2010 | 185 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2013 | 909 | 0.040 |
Why?
|
| Proprioception | 1 | 2018 | 6 | 0.040 |
Why?
|
| Weight Loss | 1 | 2022 | 462 | 0.040 |
Why?
|
| Torque | 1 | 2018 | 20 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2024 | 1469 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2018 | 55 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 531 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 71 | 0.030 |
Why?
|
| Aldehydes | 1 | 2017 | 4 | 0.030 |
Why?
|
| Athletes | 1 | 2018 | 73 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 32 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 43 | 0.030 |
Why?
|
| Proteome | 1 | 2017 | 41 | 0.030 |
Why?
|
| Stroboscopy | 1 | 2017 | 1 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2017 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 412 | 0.030 |
Why?
|
| Speech Acoustics | 1 | 2017 | 4 | 0.030 |
Why?
|
| Speech | 1 | 2017 | 9 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 206 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2017 | 14 | 0.030 |
Why?
|
| Larynx | 1 | 2017 | 19 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 128 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 169 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 102 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 193 | 0.030 |
Why?
|
| Fever | 1 | 2017 | 60 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 369 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 69 | 0.030 |
Why?
|
| Auditory Perception | 1 | 2017 | 80 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 563 | 0.030 |
Why?
|
| Shoulder Joint | 1 | 2018 | 137 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 770 | 0.030 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2017 | 205 | 0.030 |
Why?
|
| Legislation as Topic | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Solubility | 1 | 2015 | 38 | 0.030 |
Why?
|
| Heart Rate | 1 | 2017 | 345 | 0.030 |
Why?
|
| Physical Stimulation | 1 | 2015 | 83 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 780 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 78 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 86 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 24 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 98 | 0.030 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 82 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 13 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 790 | 0.030 |
Why?
|
| Immunization Schedule | 1 | 2015 | 26 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2015 | 39 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 495 | 0.030 |
Why?
|
| Liver | 1 | 2017 | 492 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 151 | 0.030 |
Why?
|
| Biopsy | 1 | 2015 | 245 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 282 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 1015 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 319 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 471 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 320 | 0.030 |
Why?
|
| Women's Health | 1 | 2015 | 235 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 1547 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 253 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2015 | 370 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1246 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2529 | 0.020 |
Why?
|
| African Americans | 1 | 2015 | 1425 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7599 | 0.010 |
Why?
|